Literature DB >> 10381045

The prevalence of hyperprolactinemia in patients with primary Sjögren's syndrome.

H J Haga1, T Rygh.   

Abstract

OBJECTIVE: To assess the prevalence of hyperprolactinemia in 55 patients with primary Sjögren's syndrome (SS), and its clinical significance.
METHODS: Concentrations of serum prolactin (PRL) were determined in 55 consecutive patients with primary SS and 110 controls by a fluoroimmunometric assay in a prospective case-control design.
RESULTS: The 55 patients with primary SS had higher serum PRL than 110 matching controls (271.5 vs 205.9 mIU/l; p < 0.02), and this difference was most evident in patients diagnosed before the age of 45 years (374.8 vs 245.5 mIU/l; p < 0.05), a patient population characterized by active immunological disease. Serum PRL did not correlate to disease duration, serum immunoglobulin, autoantibodies, or focus score in biopsies from minor salivary glands, but did correlate to score for internal organ disease (r = 0.33, p < 0.05). Two patients were diagnosed as having primary SS 12 years after hyperprolactinemia was first detected, and both patients had aggressive primary SS as indicated by extraglandular manifestations. One of the patients developed primary SS after being treated with bromocriptine, an inhibitor of PRL synthesis, for 12 years.
CONCLUSION: Patients with primary SS have moderately increased levels of serum PRL, especially evident in patients diagnosed at a young age with active immunological disease. Serum PRL is correlated to index for internal organ disease, and primary SS may be preceded by hyperprolactinemia for many years.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381045

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Sjögren's Syndrome is Associated With Reduced Lifetime Sex Hormone Exposure: A Case-Control Study.

Authors:  Sara S McCoy; Emmanuel Sampene; Alan N Baer
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-06-24       Impact factor: 4.794

2.  Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients.

Authors:  Hedi Orbach; Gisele Zandman-Goddard; Mona Boaz; Nancy Agmon-Levin; Howard Amital; Zoltan Szekanecz; Gabriella Szucs; Josef Rovensky; Emese Kiss; Andrea Doria; Anna Ghirardello; Jesus Gomez-Arbesu; Ljudmila Stojanovich; Francesca Ingegnoli; Pier Luigi Meroni; Blaz' Rozman; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 3.  Prolactin and autoimmunity.

Authors:  Luis J Jara; Gabriela Medina; Miguel A Saavedra; Olga Vera-Lastra; Carmen Navarro
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

4.  Diverse mediators modulate the chloride ion fluxes that drive lacrimal fluid production.

Authors:  Shivaram Selvam; Austin K Mircheff; Samuel C Yiu
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-26       Impact factor: 4.799

5.  2021 recommendations of the Brazilian Society of Rheumatology for the gynecological and obstetric care of patients with Sjogren's syndrome.

Authors:  Fabiola Reis Oliveira; Valeria Valim; Sandra Gofinet Pasoto; Marilena Leal Mesquita Silvestre Fernandes; Maria Lucia Lemos Lopes; Sonia Cristina de Magalhães Souza Fialho; Aysa César Pinheiro; Laura Caldas Dos Santos; Simone Appenzeller; Tania Fidelix; Sandra Lucia Euzébio Ribeiro; Danielle Christinne Soares Egypto de Brito; Tatiana Libório; Maria Carmen Lopes Ferreira Silva Santos; Leandro Tanure; Juliana DAgostino Gennari; Vinicius Tassoni Civile; Ana Carolina Pereira Nunes Pinto; César Ramos Rocha-Filho; Samira Tatiyama Miyamoto; Lissiane Karine Noronha Guedes; Alisson Pugliesi; Virginia Fernandes Moça Trevisani
Journal:  Adv Rheumatol       Date:  2021-09-03

Review 6.  Sex differences in Sjögren's syndrome: a comprehensive review of immune mechanisms.

Authors:  Jessica E Brandt; Roberta Priori; Guido Valesini; DeLisa Fairweather
Journal:  Biol Sex Differ       Date:  2015-11-03       Impact factor: 5.027

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.